Provided by Tiger Fintech (Singapore) Pte. Ltd.

Brainstorm Cell Therapeutics

1.22
+0.09007.96%
Post-market: 1.19-0.0300-2.46%19:30 EDT
Volume:518.91K
Turnover:608.83K
Market Cap:9.65M
PE:-0.53
High:1.22
Open:1.13
Low:1.12
Close:1.13
Loading ...

BrainStorm signs LOI with Minaris to manufacture NurOwn

TIPRANKS
·
27 May

BrainStorm Cell Therapeutics Partners with Minaris to Advance Phase 3b ALS Clinical Trial for NurOwn®

Reuters
·
27 May

Brainstorm Secures Key Manufacturing Partnership With Minaris for Upcoming Nurown® Phase 3B ALS Clinical Trials

THOMSON REUTERS
·
27 May

Brainstorm Cell Therapeutics Reports Q1 2025 Financials

TIPRANKS
·
20 May

Brainstorm Cell Therapeutics: Progress and Challenges in ALS Trial

TIPRANKS
·
20 May

Top Midday Gainers

MT Newswires Live
·
20 May

BrainStorm Cleared by FDA to Begin Phase 3b Trial of NurOwn for ALS

MT Newswires Live
·
19 May

BrainStorm Cell Therapeutics Inc. Receives FDA Clearance to Launch Phase 3b Trial of NurOwn® for ALS

Reuters
·
19 May

Brainstorm Receives FDA Clearance to Initiate Phase 3B Trial of Nurown® for ALS

THOMSON REUTERS
·
19 May

BrainStorm Cell Therapeutics Reports Q1 2025 Net Loss of $2.9M and EPS Improvement to $0.45

Reuters
·
16 May

Brainstorm Cell Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
16 May

Brainstorm Cell Q1 EPS $(0.45) Beats $(0.97) Estimate

Benzinga
·
16 May

Brainstorm Cell Therapeutics Inc expected to post a loss of 97 cents a share - Earnings Preview

Reuters
·
13 May

Brainstorm Cell Therapeutics Inc expected to post a loss of 97 cents a share - Earnings Preview

Reuters
·
09 May

BrainStorm's NurOwn® Data Selected as Breakthrough Science for Presentation at ISCT 2025 Meeting

PR Newswire
·
29 Apr

BrainStorm submits IND amendment to FDA for Phase 3b trial of NurOwn in ALS

TIPRANKS
·
10 Apr

Brainstorm Cell Therapeutics Submits Ind Amendment to FDA, Paving the Way for Phase 3B Trial of Nurown® in ALS

THOMSON REUTERS
·
10 Apr

Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Brainstorm Cell Therapeutics (BCLI)

TIPRANKS
·
10 Apr

Brainstorm Cell Therapeutics Inc (BCLI) Q4 2024 Earnings Call Highlights: Navigating Financial ...

GuruFocus.com
·
01 Apr

Q4 2024 Brainstorm Cell Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
01 Apr